سعر ريميست 100مجم فيال للحقن الوريدي 100 مجم/20 مل 2026

Remdesivir 100 mg concentrate (100 mg/20 ml) for intravenous infusion, single vial, marketed in Egypt.

• Treatment of COVID-19 in adults and pediatric patients (birth to <18 years, >=1.5 kg) who are hospitalized, or not hospitalized with mild-to-moderate COVID-19 at high risk of progressionDailyMed (U.S. National Library of Medicine)

• Most common (>=5%, all grades): nausea, ALT increased and AST increased.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of clinically significant hypersensitivity reactions to remdesivir or any component of the product.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity including infusion-related and anaphylactic reactions; monitor during infusion and for at least 1 hour afterwards.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Transaminase elevations; consider discontinuing if ALT rises above 10 times the upper limit of normal, discontinue if ALT elevation is accompanied by signs of liver inflammation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Chloroquine phosphate / hydroxychloroquine sulfateCo-administration not recommended (possible antagonism of antiviral activity in cell culture).DailyMed (U.S. National Library of Medicine)

• Available data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes after second- and third-trimester exposure; first-trimester data are insufficient.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Remdesivir and its metabolite GS-441524 have been detected in human milk; limited data do not indicate adverse effects in breastfed infants.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Remdesivir: Adenosine nucleotide prodrug; the active triphosphate competes with ATP for incorporation into viral RNA by SARS-CoV-2 RNA-dependent RNA polymerase, causing delayed chain termination (per directory pharmacology note and US label).